Allianz Asset Management
MLYS icon

Allianz Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Allianz Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,900
Closed -$593K – 2207
2026
Q1 		$593K Sell
21,900
-8,300
-27% -$243K ﹤0.01% 1821
2025
Q4 		$1.1M Sell
30,200
-3,500
-10% -$140K ﹤0.01% 1690
2025
Q3 		$1.28M Buy
33,700
+21,400
+174% +$463K ﹤0.01% 1656
2025
Q2 		$166K Buy
+12,300
New +$178K ﹤0.01% 1953

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Allianz Asset Management's MLYS Position: Q2 2026 in Review

Allianz Asset Management sold out of Mineralys Therapeutics (MLYS) in Q2 2026, closing a stake of 21,900 shares — an estimated $593K sold.

Allianz Asset Management first reported a position in MLYS in Q2 2025 and held it in 4 quarters. The position peaked at $1.28M in Q3 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Allianz Asset Management reported no remaining Mineralys Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Allianz Asset Management sold 21,900 Mineralys Therapeutics shares in Q2 2026, an estimated $593K.
  • Allianz Asset Management first reported a position in Mineralys Therapeutics in Q2 2025 and held it in 4 quarters.
  • Allianz Asset Management's Mineralys Therapeutics position peaked at $1.28M in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.